patritumab,trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['enhertu', 'patritumab', '$dsnky']
third instalment of a triple whammy, after patritumab and enhertu. $dsnky making a bid to consolidate its status as the winner of #asco22
Journalist at Evaluate Vantage. Proudly blocked by @JohnCendpts. Interested in: oncology, immunology. Not interested in: what stock you bought today.